Comparing the biological impact of glatiramer acetate with the biological impact of a generic

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Towfic, Fadi ^a   Funt, Jason M ^a   Fowler, Kevin D ^a   Bakshi, Shlomo ^b   Blaugrund, Eran ^b   Artyomov, Maxim N ^a   Hayden, Michael R ^b   Ladkani, David ^b   Schwartz, Rivka ^b   Zeskind, Benjamin ^a  

^a Immuneering Corporation   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; GLATIMER; GLATIRAMER; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL TYPE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EXPOSURE; GENE EXPRESSION; IMMUNE SYSTEM; MATHEMATICAL COMPUTING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; CELL LINEAGE; DRUGS, GENERIC; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; IMMUNE SYSTEM; MICE; MONOCYTES; PEPTIDES; RECEPTORS, G-PROTEIN-COUPLED; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 84897389522     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083757     Document Type: Article

References (45)

1. Greenwood JC (2010) Biotechnology: Delivering on the Promise. Sci Transl Med 2: 13cm1-13cm1. doi:10.1126/scitranslmed.3000357.
2. Kozlowski S, Woodcock J, Midthun K, Sherman RB (2011) Developing the Nation's Biosimilars Program. New England Journal of Medicine 365: 385-388. doi:10.1056/NEJMp1107285.
3. Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin J-H, et al. (2012) Setting the stage for biosimilar monoclonal antibodies. Nature Biotechnology 30: 1179-1185. doi:10.1038/nbt.2447.
4. Ebbers HC, Crow SA, Vulto AG, Schellekens H (2012) Interchangeability, immunogenicity and biosimilars. Nature Biotechnology 30: 1186-1190. doi:10.1038/nbt.2438.
5. Holloway C, Mueller-Berghaus J, Lima BS, Lee SL, Wyatt JS, et al. (2012) Scientific considerations for complex drugs in light of established and emerging regulatory guidance. Annals of the New York Academy of Sciences 1276: 26-36. doi:10.1111/j.1749-6632.2012.06811.x.
6. Schellekens H, Klinger E, Mühlebach S, Brin J-F, Storm G, et al. (2011) The therapeutic equivalence of complex drugs. Regulatory Toxicology and Pharmacology 59: 176-183. doi:10.1016/j.yrtph.2010.09.021.
7. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G (2010) Multiple sclerosis: risk factors, prodromes, and potential causal pathways. The Lancet Neurology 9: 727-739. doi:10.1016/S1474-4422(10)70094-6.
8. Rosati G (2001) The prevalence of multiple sclerosis in the world: an update. Neurol Sci 22: 117-139.
9. Lowther DE, Hafler DA (2012) Regulatory T cells in the central nervous system. Immunol Rev 248: 156-169. doi:10.1111/j.1600-065X.2012.01130.x.
10. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA (2000) Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. Journal of Clinical Investigation 105: 967-976. doi:10.1172/JCI8970. (Pubitemid 30203069)
11. Arnon R (2004) Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proceedings of the National Academy of Sciences 101: 14593-14598. doi:10.1073/pnas. 0404887101.
12. Carpintero R, Brandt KJ, Gruaz L, Molnarfi N, Lalive PH, et al. (2010) Glatiramer acetate triggers PI3K/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes. Proceedings of the National Academy of Sciences 107: 17692-17697. doi:10.1073/pnas.1009443107.
13. Ruggieri M, Avolio C, Livrea P, Trojano M (2007) Glatiramer Acetate in Multiple Sclerosis: A Review. CNS Drug Reviews 13: 178-191. doi:10.1111/j.1527- 3458.2007.00010.x. (Pubitemid 47052348)
14. Varkony H, Weinstein V, Klinger E, Sterling J, Cooperman H, et al. (2009) The glatiramoid class of immunomodulator drugs. Expert Opinion on Pharmacotherapy 10: 657-668. doi:10.1517/14656560902802877.
15. Bakshi S, Chalifa-Caspi V, Plaschkes I, Perevozkin I, Gurevich M, et al. (2013) Gene expression analysis reveals functional pathways of glatiramer acetate activation. Expert Opinion on Therapeutic Targets 17: 351-362. doi:10.1517/14728222.2013.778829.
16. Bolstad BM (2013) preprocessCore: A collection of pre-processing functions. Available: http://www.bioconductor.org/packages/2.13/bioc/html/ preprocessCore.html.
17. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostat 8: 118-127. doi:10.1093/biostatistics/kxj037. (Pubitemid 44906106)
18. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD (2013) sva: Surrogate Variable Analysis. Available: http://www.bioconductor.org/packages/release/ bioc/html/sva.html.
19. Ho JWK, Stefani M, dos Remedios CG, Charleston MA (2008) Differential variability analysis of gene expression and its application to human diseases. Bioinformatics 24: i390-398. doi:10.1093/bioinformatics/btn142. (Pubitemid 351911695)
20. Quackenbush J (2002) Microarray data normalization and transformation. Nature Genetics 32: 496-501. doi:10.1038/ng1032.
21. Pavlidis P (2003) Using ANOVA for gene selection from microarray studies of the nervous system. Methods 31: 282-289.
22. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological): 289-300.
23. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3. doi:10.2202/1544-6115.1027.
24. Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer. pp. 397-420.
25. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80. doi:10.1186/gb-2004-5-10-r80.
26. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nature Genetics 38: 500-501. doi:10.1038/ng0506-500.
27. Saeys Y, Inza I, Larrañaga P (2007) A review of feature selection techniques in bioinformatics. Bioinformatics 23: 2507-2517. doi:10.1093/ bioinformatics/btm344. (Pubitemid 350048351)
28. Zheng Y, Josefowicz SZ, Kas A, Chu T-T, Gavin MA, et al. (2007) Genomewide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445: 936-940. doi:10.1038/nature05563.
29. Eppig JT, Blake JA, Bult CJ, Kadin JA, Richardson JE (2012) The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res 40: D881-D886. doi:10.1093/nar/gkr974.
30. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550. doi:10.1073/pnas.0506580102. (Pubitemid 41528093)
31. Benita Y, Cao Z, Giallourakis C, Li C, Gardet A, et al. (2010) Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor. Blood 115: 5376-5384. doi:10.1182/blood-2010-01-263855.
32. Painter MW, Davis S, Hardy RR, Mathis D, Benoist C (2011) Transcriptomes of the B and T lineages compared by multi-platform microarray profiling. J Immunol 186: 3047-3057. doi:10.4049/jimmunol.1002695.
33. Sugimoto N (2006) Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. International Immunology 18: 1197-1209. doi:10.1093/intimm/dxl060.
34. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, et al. (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nature Medicine 13: 935-943. doi:10.1038/nm1620. (Pubitemid 47222047)
35. Wang Z (2006) Role of IFN-g in induction of Foxp3 and conversion of CD4+CD25- T cells to CD4+ Tregs. Journal of Clinical Investigation. Available: http://www.jci.org/articles/view/25826/pdf. Accessed: 18 Feb 2013.
36. Hong J, Li N, Zhang X, Zheng B, Zhang JZ (2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 102: 6449-6454. doi:10.1073/pnas.0502187102. (Pubitemid 40617463)
37. Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, et al. (2009) Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1b in human monocytes and multiple sclerosis. Proceedings of the National Academy of Sciences 106: 4355-4359.
38. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, et al. (2010) Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 115: e10-e19. doi:10.1182/blood-2009-07-235028.
39. Nylander A, Hafler DA (2012) Multiple sclerosis. Journal of Clinical Investigation 122: 1180-1188. doi:10.1172/JCI58649.
40. Dhib-Jalbut S, Boppana S, Valenzuela R, Khan O, Ito K (2012) Clinical response to glatiramer acetate correlates with an increase in activated and memory CD45RA-Foxp3+CD4+ T-cells. ECTRIMS.
41. Bar-Or A, Nuttall RK, Duddy M, Alter A, Kim HJ, et al. (2003) Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 126: 2738-2749. doi:10.1093/brain/awg285. (Pubitemid 37463092)
42. Pul R, Morbiducci F, Škuljec J, Skripuletz T, Singh V, et al. (2012) Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients. PLoS ONE 7: e51867. doi:10.1371/journal.-pone.0051867.
43. Anis S, Sonis P, Hanael E, Gurevich M, Achiron A (2013) Gene Expression Biomarkers for Glatiramer Acetate Treatment Response in Relapsing-Remitting Multiple Sclerosis (P05.142). AAN. Available: http://www.neurology.org/cgi/ content/meeting-abstract/80/1-MeetingAbstracts/P05.142.
44. Anis S, Hanael E, Sonis P, Gurevich M, Achiron A (2010) Good responders to glatiramer acetate treatment identified by gene expression classifiers. ECTRIMS.
45. Nicholas JM, Teva (2009) Citizen Petition Requesting That FDA Not Approve An Abbreviated New Drug Application Referencing Copaxone® (glatiramer acetate injection) Until Certain Conditions Are Met. FDA-2009-P-0555. Available: http://www.regulations.gov/#! documentDetail;D = FDA-2009-P-0555-0001.